Nexavar cleared for liver cancer in Japan
This article was originally published in Scrip
Executive Summary
Bayer/ Onyx Pharmaceuticals' Nexavar (sorafenib) has been approved in Japan for the additional indication of advanced hepatocellular carcinoma (HCC).